EN
- Bifidobacterium breve CCFM1217
- Bifidobacterium longum CCFM1216
- Lactobacillus reuteri CCFM1135
- 1) Reduces TMAO and Prevents Atherosclerosis
- 2) Beneficial for blood lipids and glucose
- 3) Reducing plasma trimethylamine oxidation
MetaAKK™ Dietary Metabolism - Prevent Atherosclerosis
Formulation
Functionality
Scientific Support
Pre-clinical paper
1) Bifidobacterium longum Ameliorates Intestinal Inflammation and Metabolic Biomarkers in Mice Fed a High-Fat Diet with Gliadin by Indoleacrylic Acid.
2) Bifidobacterium breve and Bifidobacterium longum Attenuate Choline-Induced Plasma Trimethylamine N-Oxide Production by Modulating Gut Microbiota in Mice.
Patent
1) (CCFM1217) Jiangnan University, Bifidobacterium breve CCFM1217 capable of simultaneously reducing plasma and cecal trimethylamine (TMA) and its application. Chinese Invention Patent, CN114381406A.
2) (CCFM1216) Jiangnan University, Bifidobacterium longum CCFM1216 for reducing plasma TMAO and alleviating/preventing atherosclerosis and its application. Chinese Invention Patent, CN114410531A.
3) (CCFM1135) Jiangnan University, Application of Lactobacillus reuteri CCFM1135 in reducing plasma trimethylamine N-oxide. Chinese Invention Patent, CN114404459B.